Get started
IAG (IAG.mc) bullish scenario:The technical figure Triangle can be found in the Spanish company International Consolidated Airlines Group S.A. (IAG.mc) at daily chart. International Consolidated Airlines Group S.A., trading as International Airlines Group and usually shortened to IAG, is an Anglo-Spanish multinational airline holding company. It was formed in January 2011 after a merger agreement between British Airways and Iberia, the flag carriers of the United Kingdom and Spain respectively, when British Airways and Iberia became wholly owned subsidiaries of IAG. The Triangle has broken through the resistance line on 10/02/2022, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 21 days towards 2.2830 EUR. Your stop loss order according to experts should be placed at 1.8120 EUR if you decide to enter this position. IAG is set to cancel its takeover of Air Europa after European regulators indicated they would not allow it to go through without further concessions, though CEO Luis Gallego hasn't given up hope of some sort of tie-up. British Airways and Iberia owner IAG's proposed acquisition from privately held Spanish company Globalia was designed to help the group's Madrid hub to compete more effectively against its European rivals. Air Europa provides connections to Latin America as well as serving destinations in Europe. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
BME:IAGLong
by legacyFXofficial
DIA: the worst has passed, price recovery underwayAfter a difficult year after the capital increase back in August, it the worst case scenario has already passed, and investors bought the dip and pushing the price higher. The stock is a small cap, so remember, it's more volatile than other stocks and hype moments could increase the price dramatically like these past two days. Next stop 0.02, and if broken out, next one would be at 0.023. Regarding its fundamentals, the CEO bought shares, so that's a good indicative that the changes they're doing are being effective. They closed all supermarkets that were experiencing huge losses, thus reducing the risk in the company. Also, they're revamping all the stores and real revenue won't be reflected until 2023. 2022 will be the key year for DIA. We are long on this one for the long term.
BME:DIALong
by alvaromroo
1
Enagas: Top pick for a dividend strategyWith a yearly dividend yield of 6.6%, it is at the current moment one of the bests in the Spanish stock exchange. Moreover, from the technical analysis perspective, we have a strong support level on the daily chart (19.47 from last candle) and on the weekly chart (17.71). We have in our HT 200 portfolio for the long term and so far we have +10.70% + dividends. 2022 looks a year for value investing and dividend investors, as they are become more risk averse in comparison to 2020 and the increasing inflation, so we believe companies such as Enagas, with a reliable net income in all quarters, offer a safe heaven for these type of investors.
BME:ENGLong
by alvaromroo
1
Naturgy: Megabullish trendIt's not very common to see a Spanish dividend stock performing like this these days but the Australian fund IFM is trying to increase its stake in Naturgy and nobody is willing to sell the stock cheap. From the technical analysis perspective, there are no resistance level until last highs of 2007 (38.83). Although we are in overbought territory, we don't recommend to sell a winner like this one, especially if you bought it when it had a better dividend yield than it has today. As long as there are no signals of weaknesses on the IBEX 35 in the weekly or monthly charts such as bearish divergences, hold it.
BME:NTGYLong
by alvaromroo
2
Telefonica: The perfect choice for a DIVIDEND strategyHere at Human Traders, we've been following Telefonica closely. Its fundamentals look better than ever. They reduced its debt from €56Bn in 2011 to €25bn in 2021. Alvaro Pallete, CEO of Telefonica has done an incredible job in term of debt reduction and company management. The dividend is also very interesting. We bought Telefonica when the dividend yield was more than 12%. Still the dividend yield now is more than 6%, one of the bests in Spain, a country where almost every company offers attractive dividend yields. In terms of competition, the telecommunication sector has always been fierce, but Telefonica remains as the main company in the sector in Spain and strong presence in LATAM. With Movistar+, they follow the same strategy plan as AT&T with streaming services. Regarding technical analysis, you can clearly see the downtrend of the last 15 years has been really strong, but we believe this time there could be a breakout of the main resistance level. It will take some time, but with this high-dividend yield, we can wait as long as we need. If you follow a dividend strategy, we recommend to have this one in your portfolio. For those who follow performance only, wait for the breakout of the resistance level to enter, o enter on the bottom area of the last channel. As you can see there was an important bullish divergence last year, and we don't expect the stock price to fall below that area, unless there is another market crisis like the one we saw back in March 2020. There is also the possibility of a rally in the telecommunication sector, one the most smashed sectors in the last 15 years, but interestingly, it's one of the most important ones in society.
BME:TEFLong
by alvaromroo
1
Market phases explained through ACS' graphA few days ago, I identified the different market phases through this company's graph: uptrend, distribution and downtrend, which could imply that the market is right now within the accumulation phase. This phase is characterized by the price of these shares being lateral and, when this phase ends, a new trend will begin. Therefore, I consider that keeping an eye on this company can be interesting in order to identify the brand new trend as it starts, so that we can open positions in favour of it. If we have a closer look at the last candles that have been drawn in this graph, we can appreciate that the price of these shares has recently tried to break the accumulation range downwards. Nevertheless, buyers have been strong enough as to not let sellers to. The uncertainty surrounding the price's future direction is still there, so we will keep on waiting until we observe a clear brekout.
BME:ACS
by mar_lpz
REPSOL, S.A. REBOUND FROM DAILY SUPPORT LINELooking at the technical picture of the Repsol SA stock on our daily chart, we can see that from the end of October, the share price has been drifting lower while trading below a short-term tentative downside resistance line. The experts said that overall, the stock continues to trade above a medium-term tentative upside support line, which may lead to some higher areas again if it stays intact, however, given that the share price is stuck between the two lines. Repsol S.A. operates as an integrated energy company worldwide, and its financial statistic indicators look so relevant with PE Ratio 13.3 and with earnings forecast of 4.97% per year. But according to the experts, the company is still overvalued at the current price with a fair share price of 6.41 EUR per share. Suppose the stock breaks the previously discussed upside line and falls below the 10.01 hurdle, marked by the inside swing that could clear the path to further declines. REP might send the stock to the 9.74 zones, which could provide a temporary hold-up. That said, if there are still no new buyers' insight, the slide may continue, and the next target could be at 9.46. A break of the aforementioned downside line and then a push above the 10.82 hurdles and the high of yesterday could open the door for higher areas, as more buyers might join in. REP may then drift to the 11.21 obstacle or even the 11.39. If the buyers don’t stop there, the next possible target could be at 11.78, marked by the highest point of October. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carry a high-risk level. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and such sites. Furthermore, one understands that the company carries zero influence over transactions, needs, and trading signals. Therefore, it cannot be held liable nor guarantee any profits or losses.
BME:REP
by legacyFXofficial
1
Are we at the bottom yet?Grifols stock has been heavely punished during 2021. First the pandemic difficulted the plasma collection. We must take into account the stimulus checks and the unemployment benefits from the US goverment wich might have disuaded people from going to the plasma collection centers to get some extra income. I'll be looking forward for the data on the plasma operations in the next earnings release. We also have to consider the high net gearing of the company after issuing a ton of debt to purchase various companies wich will allow BME:GRF . GRF .to diversify their portfolio in the future and increase their "plasma economy" being able to extract more proteins and produce more drugs (and thus revenue) from each liter of plasma. The real question is if Grifols is a good buy at 19-20 euros per share. It is important to consider that the company has announced that it will suspend its dividend until its debt is reduced, so this makes it a less attractive long term hold. If we look at the chart we can see that we are really close to two important support levels at 20 eur and 19.5 eur that acted as resistance between 2016-2017. I consider that this might be a great entry point consdering the position of GRF in the plasma market, there aren't many competitors or substitutives to their products. The future of the stock and the shareholder value shall come from a change in the fundamentals once they get the possibility to reduce the collection cost of plasma (reducing how much they pay the donors) and thus they see and increase in their gross and net margins. Another important aspect would be the reinstitution of its dividends but you don't sell the skin till you have caught the bear. It will take some time and it would require their operations to return to normal. Overall i think that if you take all this factors into consideration the price between 19.5 and 20 euro can be a good entry if you want to bet on their earnings pointing towards a return to normal. If we get good guidance on Q3 earnigns i wouldn't be surprise to see the stock going above the 22 euro mark (a 10% return from where it is currently trading) and even getting close to 25 euro. I don't see GRF going back to their prepandemic levels any time soon but i think there might be some value on this price point if the situation of the company improves towards the next year. In an enviroment where there are concerns of inflation and stagnation a company with a stable stream of income and control over its prices can provide some defense for investors trying to preserve value.
BME:GRFLong
by CaptnBNZ